循环肿瘤DNA在头颈癌中的应用:美国头颈学会综述
美国头颈学会综述评估循环肿瘤DNA(ctDNA)在头颈癌中的当前效用,重点讨论HPV相关口咽癌和EBV相关鼻咽癌的致癌病毒DNA作为生物标志物。综述回顾正在进行的临床试验,讨论ctDNA在监测治疗反应和检测微小残留病(MRD)方面的作用。结论认为靶向病毒ctDNA的液体活检在诊断和监测中前景可期,但常规临床应用仍存检测变异性和结果不准确等问题,需优化试验设计与进一步研究。
要点
- 靶向病毒ctDNA的液体活检是头颈癌诊断和监测中有前景的生物标志物。
- ctDNA可用于监测治疗反应和评估微小残留病(MRD)。
- 常规临床应用仍面临检测变异性和不准确结果的影响等问题。
核心结论
- 靶向病毒ctDNA的液体活检是头颈癌诊断和监测中有前景的生物标志物。
- 正在进行临床试验将阐明ctDNA如何用于监测治疗反应、评估MRD并以精准肿瘤学方式调整治疗决策。
研究设计与样本
- 美国头颈学会开展的综述,回顾正在进行的临床试验并讨论ctDNA当前效用。
主要发现
- 随着HPV相关口咽癌和EBV相关鼻咽癌的出现,ctDNA和致癌病毒DNA成为有前景的生物标志物。
- ctDNA在精准肿瘤学推进中有前景,但常规临床应用仍存检测变异性和不准确结果影响等问题。
临床怎么用
- 靶向病毒ctDNA的液体活检可用于头颈癌诊断和监测场景。
- ctDNA有望用于监测治疗反应、评估MRD并以精准肿瘤学方式辅助治疗决策。
局限性
- ctDNA常规临床应用仍存检测变异性和不准确检测结果影响等问题。
- 需优化临床试验设计和进一步研究才能将ctDNA推向头颈癌管理前沿。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Despite gains in understanding head and neck cancer over the past several decades, the discovery of reliable biomarkers remains elusive. With the advent of human papillomavirus-associated oropharynx cancer and Epstein-Barr virus-associated nasopharynx cancer, circulating tumor DNA (ctDNA) and oncogenic viral DNA have emerged as potentially promising biomarkers. OBSERVATIONS: A review was conducted by the American Head and Neck Society to address the current utility of ctDNA. Ongoing clinical trials were reviewed, with discussion of its utility in monitoring treatment response and measuring minimal residual disease (MRD). Although ctDNA holds promise in the push for precision oncology, several questions remain regarding its routine clinical use, including test variability and implications of inaccurate test results. Optimized clinical trial designs and further research are necessary to bring ctDNA to the forefront of head and neck cancer management. CONCLUSIONS AND RELEVANCE: Liquid biopsy targeting viral ctDNA is a promising biomarker in the diagnostic and surveillance settings across head and neck cancer types. Ongoing clinical trials will help elucidate how ctDNA can be implemented to monitor treatment response, assess MRD, and frame treatment decisions to adapt treatment via a precision oncology approach.
引用
- Kansara S, Contrera K, Roof S, et al. Circulating Tumor DNA in Head and Neck Cancer: A Review From the American Head and Neck Society. JAMA Otolaryngol Head Neck Surg. 2026. PMID: 42530947. doi:10.1001/jamaoto.2026.2045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。